ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For CML, the patient received imatinib 400 mg daily and achieved complete cytogenetic and major molecular remission with a reduction in BCR-ABL/ABL ratio from 15.05 to 0.07 after three months.